Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
AMAG is in the long-term down -84% below S&P in 7 years.
Description: AMAG Pharmaceuticals, Inc. develops and commercializes specialty pharmaceutical products. The company markets Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It markets Feraheme in the United States and Canada; and as Rienso in the European Union. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as an IV iron rep
|Shares Outstanding||EPS||1.11||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||385.93%||Sales Growth - Q/Q||38.41%||P/E||14.77|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||11.63%||ROE||26.74%||ROI||15.98%|
|Current Ratio||1.71||Quick Ratio||1.61||Long Term Debt/Equity||1.51||Debt Ratio||0.45|
|Gross Margin||81.03%||Operating Margin||31.1%||Net Profit Margin||65.25%||Dividend Payout Ratio|
|Cash From Financing Activities||183.64 M||Cash From Investing Activities||-284.74 M||Cash From Operating Activities||71.69 M||Gross Profit||104.2 M|
|Net Profit||33.26 M||Operating Profit||61.12 M||Total Assets||1.64 B||Total Current Assets||555.48 M|
|Total Current Liabilities||323.97 M||Total Debt||483.2 M||Total Liabilities||926.3 M||Total Revenue||123.88 M|
|High 52 week||25.65||Low 52 week||10.34||Last close||10.34||Last change||-4.08%|
|RSI||40.26||Average true range||0.72||Beta||0.76||Volume||768.3 K|
|Simple moving average 20 days||-8.89%||Simple moving average 50 days||-14.38%||Simple moving average 200 days||-41.9%|
|Performance Week||-10.32%||Performance Month||-13.18%||Performance Quart||-38.12%||Performance Half||-56.92%|
|Performance Year||-21.96%||Performance Year-to-date||-31.93%||Volatility daily||4.01%||Volatility weekly||8.97%|
|Volatility monthly||18.39%||Volatility yearly||63.7%||Relative Volume||235.39%||Average Volume||747.72 K|
|New High||New Low|
2019-11-13 08:00:00 | AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
2019-11-07 11:44:09 | Hedge Funds Are Still Bullish On AMAG Pharmaceuticals AMAG
2019-11-06 06:18:11 | AMAG Sees Hammer Chart Pattern: Time to Buy?
2019-11-04 11:18:04 | AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates
2019-11-03 22:36:08 | Edited Transcript of AMAG earnings conference call or presentation 1-Nov-19 12:00pm GMT
2019-11-01 08:15:12 | AMAG Pharmaceuticals AMAG Reports Q3 Loss, Lags Revenue Estimates
2019-10-31 11:36:03 | The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG
2019-10-30 16:23:30 | Biotech Dives After Panel Votes To Pull Its Drug Following Failed Test
2019-10-30 10:56:02 | Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More
2019-10-30 10:15:02 | What's in Store for GW Pharmaceuticals GWPH in Q3 Earnings?
2019-10-30 09:20:17 | AMAG Pharmaceuticals Falls 25% After FDA Recommends Removing Makena From The Market
2019-10-29 17:05:51 | FDA committee votes to pull labor-halting drug from market
2019-10-29 10:29:02 | AMAG Pharmaceuticals, Inc. AMAG Shares March Higher, Can It Continue?
2019-10-29 10:25:02 | Is a Beat in Store for Amarin AMRN This Earnings Season?
2019-10-28 16:21:41 | This Biotech Stock Popped — But Could The FDA Pull Its Key Drug?
2019-10-27 12:56:58 | The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
2019-10-08 08:45:37 | UPDATE 2-Amag settles with activist Caligan, adds two board directors
2019-10-08 08:00:00 | AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP
2019-09-28 09:05:00 | Here's Why AMAG Pharmaceuticals NASDAQ:AMAG Can Afford Some Debt
2019-09-26 08:00:00 | Caligan Partners Issues Letter to AMAG Shareholders
2019-09-25 08:00:00 | AMAG Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
2019-09-23 08:00:00 | AMAG Files Definitive Consent Revocation Statement and Sends Letter to Shareholders
2019-09-20 08:44:07 | UPDATE 2-Camber Capital to discuss Amag's board composition with shareholders
2019-09-20 08:20:07 | Camber Capital says Amag Pharma's shares undervalued, seeks changes
2019-09-12 08:00:00 | AMAG Sends Letter to Shareholders
2019-09-06 09:31:01 | Why Is AMAG Pharmaceuticals AMAG Up 27.3% Since Last Earnings Report?
2019-09-05 06:24:51 | Activist investor pushes for ex-Goop CEO, others to join board of Waltham drugmaker Amag
2019-09-04 09:45:46 | Activist Investor Seek Four Board Seats at Amag Pharmaceuticals
2019-08-16 10:42:02 | Palatin's PTN to Report Q4 Earnings: What's in the Cards?
2019-08-16 06:20:45 | Gene therapies to test FDA's approach to regulating drugs after launch, experts say
2019-08-15 14:23:00 | [video]New York Investment Firm Discloses 10.3% Amag Stake, May Propose Changes
2019-08-14 13:39:58 | Have Insiders Been Buying AMAG Pharmaceuticals, Inc. NASDAQ:AMAG Shares?
2019-08-13 11:42:22 | Jim Cramer Shares His Thoughts On Delta Air Lines, Okta And More